Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation.
about
Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Levodopa/carbidopa/entacapone ...... ysis, and economic evaluation.
@en
Levodopa/carbidopa/entacapone ...... ysis, and economic evaluation.
@nl
type
label
Levodopa/carbidopa/entacapone ...... ysis, and economic evaluation.
@en
Levodopa/carbidopa/entacapone ...... ysis, and economic evaluation.
@nl
prefLabel
Levodopa/carbidopa/entacapone ...... ysis, and economic evaluation.
@en
Levodopa/carbidopa/entacapone ...... ysis, and economic evaluation.
@nl
P2093
P2860
P356
P1476
Levodopa/carbidopa/entacapone ...... ysis, and economic evaluation.
@en
P2093
Suo-Di Zhai
Ting-Ting Qiu
Zhan-Miao Yi
P2860
P304
P356
10.2147/TCRM.S163190
P50
P577
2018-04-16T00:00:00Z